• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Phathom Pharmaceuticals Inc (NQ: PHAT )

    11.88 +0.94 (+8.59%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 809,138
    Open 10.99
    Bid (Size) 11.50 (1)
    Ask (Size) 12.00 (20)
    Prev. Close 10.94
    Today's Range 10.80 - 12.13
    52wk Range 6.065 - 17.02
    Shares Outstanding 43,614,075
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
    Each of the following seven heavily-shorted stocks may have what it takes to become one of the next big short squeeze stocks. 
    Via InvestorPlace

    Performance

    YTD
    +29.55%
    +29.55%
    1 Month
    +9.70%
    +9.70%
    3 Month
    +31.85%
    +31.85%
    6 Month
    +51.34%
    +51.34%
    1 Year
    -12.20%
    -12.20%

    More News

    Read More
    Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
    Via InvestorPlace
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Preview: Phathom Pharmaceuticals's Earnings
    Via Benzinga
    Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    The 3 Best Healthcare Stocks to Buy in May 2024
    Via InvestorPlace
    PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Earnings Scheduled For March 7, 2024
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
    Via Benzinga
    Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.